Mass Cytometry based Immune Cell & Blood Cell Interaction Analysis Service

Background

As immune effector cell (IEC) therapies continue to evolve, characterizing the downstream impact of these powerful agents on hematopoietic integrity has become a central concern in next-generation safety assessment strategies. Traditional assays often fall short in capturing the full complexity of immune–hematopoietic interactions, which involve diverse signaling axes, lineage-specific perturbations, and dynamic microenvironmental responses.

Mass cytometry (CyTOF) stands at the forefront of high-dimensional single-cell analysis. By integrating flow cytometry with mass spectrometry, this technology enables simultaneous quantification of 40+ cellular parameters without signal overlap, allowing for unprecedented resolution of immune and hematopoietic phenotypes. At Creative Biolabs, our Mass Cytometry based Immune Cell and Blood Cell Interaction Analysis Service provides a platform to dissect the multiplexed, non-redundant biological processes underlying immune cell–induced hematopoietic suppression or modulation.

Fig.1 The subsets of leukocytes and their surface markers used to identify them.¹

This service is a core component of our Immune Effector Cell-associated Hematotoxicity (ICAHT) Management Solutions, offering researchers actionable insights into lineage-specific vulnerability, progenitor status, cell state transitions, and functional remodeling in response to engineered immune effectors.

Service Overview

Creative Biolabs' CyTOF-based platform is designed to map the immunophenotypic and functional profiles of both IECs and hematopoietic cells post co-culture or ex vivo exposure. Using meticulously designed metal-tagged antibody panels, we interrogate critical cell surface and intracellular markers associated with:

Unlike conventional flow cytometry, mass cytometry eliminates spectral overlap, enabling deeper multiplexing with improved signal fidelity. Our panels are modular and customizable, allowing tailored profiling to specific CAR constructs, targets, or hematopoietic populations of interest.

This service supports both discovery-phase research and comparative construct analysis, offering a scalable solution to understand hematopoietic risks and inform upstream design choices.

Core Capabilities

Workflow

Highlights

FAQs

Contact Us

Creative Biolabs is committed to advancing safe, precise, and mechanism-driven immune effector cell development. Our Mass Cytometry based Immune Cell and Blood Cell Interaction Analysis Service provides deep phenotypic and functional insights into how engineered immune cells interact with hematopoietic targets—accelerating design decisions and reducing downstream toxicity risks.

Let's co-engineer next-gen immune therapies with confidence. Reach out today to explore a collaborative solution built for discovery and safety.

Reference

1. Arlt, Elise et al. "A Flow Cytometry-Based Examination of the Mouse White Blood Cell Differential in the Context of Age and Sex." Cells vol. 13,18 1583. DOI: 10.3390/cells13181583. Distributed under Open Access License CC BY 4.0, without modification.